MY162737A
(en)
|
2010-09-09 |
2017-07-14 |
Pfizer |
4-1bb binding molecules
|
ES2724801T3
(es)
*
|
2011-04-19 |
2019-09-16 |
Pfizer |
Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
|
TWI617578B
(zh)
|
2012-05-30 |
2018-03-11 |
Chugai Pharmaceutical Co Ltd |
標的組織專一的抗原結合分子
|
US9834610B2
(en)
*
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
US9944992B2
(en)
|
2013-03-15 |
2018-04-17 |
The University Of Chicago |
Methods and compositions related to T-cell activity
|
EP3783017A1
(en)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
CA2925421C
(en)
|
2013-09-24 |
2023-08-29 |
Medicenna Therapeutics, Inc. |
Interleukin-2 fusion proteins and uses thereof
|
WO2015069703A1
(en)
*
|
2013-11-06 |
2015-05-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
TWI702316B
(zh)
|
2013-12-04 |
2020-08-21 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
AR099379A1
(es)
|
2013-12-24 |
2016-07-20 |
Bristol Myers Squibb Co |
Compuestos tricíclicos como agentes antineoplásicos
|
ES2783026T3
(es)
|
2014-02-04 |
2020-09-16 |
Pfizer |
Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
|
KR101503341B1
(ko)
|
2014-03-12 |
2015-03-18 |
국립암센터 |
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
|
EP3134102B1
(en)
|
2014-04-24 |
2019-07-03 |
The Board of Trustees of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
JP2017517506A
(ja)
|
2014-05-21 |
2017-06-29 |
ファイザー・インコーポレイテッド |
癌を処置するための抗ccr4抗体および4−1bbアゴニストの併用
|
EA037006B1
(ru)
|
2014-06-06 |
2021-01-26 |
Бристол-Майерс Сквибб Компани |
Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
|
CN106535884A
(zh)
|
2014-06-06 |
2017-03-22 |
弗雷克萨斯生物科学公司 |
免疫调节剂
|
EP3185866A1
(en)
|
2014-08-25 |
2017-07-05 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
EP3215141A4
(en)
|
2014-11-05 |
2018-06-06 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
PT3221363T
(pt)
|
2014-11-21 |
2020-07-23 |
Bristol Myers Squibb Co |
Anticorpos contra cd73 e utilizações dos mesmos
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
SI3247728T1
(sl)
|
2015-01-20 |
2020-09-30 |
Igm Biosciences, Inc. |
Super-družina receptorjev, ki vežejo molekule TNF (dejavnik tumorske nekroze), in njihova uporaba
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
JP2018508509A
(ja)
|
2015-02-22 |
2018-03-29 |
ソレント・セラピューティクス・インコーポレイテッド |
Cd137に結合する抗体医薬
|
SG10201810615VA
(en)
|
2015-02-26 |
2019-01-30 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
MX371167B
(es)
|
2015-03-02 |
2020-01-21 |
Rigel Pharmaceuticals Inc |
Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
|
TW201700453A
(zh)
|
2015-04-03 |
2017-01-01 |
必治妥美雅史谷比公司 |
Ido抑制劑
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
DK3283527T3
(da)
|
2015-04-13 |
2021-03-08 |
Five Prime Therapeutics Inc |
Kombinationsterapi mod cancer
|
US10683290B2
(en)
|
2015-05-11 |
2020-06-16 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
EP3307740B1
(en)
|
2015-05-12 |
2019-12-18 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
AU2016262845B2
(en)
*
|
2015-05-18 |
2020-07-23 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
BR112017024770A2
(pt)
*
|
2015-05-21 |
2018-07-31 |
Alligator Bioscience Ab |
polipeptídeos inovadores
|
US20180237534A1
(en)
|
2015-05-29 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
GB201509338D0
(en)
*
|
2015-05-29 |
2015-07-15 |
Bergenbio As |
Combination therapy
|
IL256245B
(en)
|
2015-06-16 |
2022-09-01 |
Merck Patent Gmbh |
Treatments that combine a pd-l1 antagonist
|
AU2016291817A1
(en)
|
2015-07-16 |
2018-02-22 |
Biolinerx Ltd. |
Compositions and methods for treating cancer
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
WO2017035118A1
(en)
|
2015-08-25 |
2017-03-02 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
CN113214398B
(zh)
|
2015-09-22 |
2022-04-08 |
苏州丁孚靶点生物技术有限公司 |
抗人cd137的完全人抗体及其应用
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
US10273281B2
(en)
|
2015-11-02 |
2019-04-30 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
BR112018008904A2
(pt)
|
2015-11-03 |
2018-11-27 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a tim-3 e seus usos
|
GB201519481D0
(en)
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
CN116327924A
(zh)
|
2015-11-23 |
2023-06-27 |
戊瑞治疗有限公司 |
用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
|
JP6856648B2
(ja)
|
2015-12-15 |
2021-04-07 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Cxcr4受容体アンタゴニスト
|
BR112018013677A2
(pt)
*
|
2016-01-11 |
2019-01-22 |
Inhibrx Inc |
proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
|
US20190031765A1
(en)
|
2016-01-25 |
2019-01-31 |
Pfizer Inc. |
Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
|
EP3423494A1
(en)
|
2016-03-04 |
2019-01-09 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
CN116059351A
(zh)
|
2016-04-18 |
2023-05-05 |
塞德斯医疗公司 |
结合人cd40的激动性抗体及其用途
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
JP2019522627A
(ja)
|
2016-05-04 |
2019-08-15 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
US10544099B2
(en)
|
2016-05-04 |
2020-01-28 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3452030A4
(en)
|
2016-05-04 |
2019-11-13 |
Bristol-Myers Squibb Company |
INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3464362B1
(en)
*
|
2016-05-27 |
2020-12-09 |
AbbVie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
US20170342169A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Bispecific binding proteins
|
CA3028134A1
(en)
|
2016-06-17 |
2017-12-21 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of cd117+ cells
|
EP3471753A1
(en)
|
2016-06-20 |
2019-04-24 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
MA45672A
(fr)
|
2016-07-14 |
2019-05-22 |
Biontech Ag |
Anticorps multispécifiques dirigés contre cd40 et cd137
|
PE20190418A1
(es)
|
2016-07-14 |
2019-03-19 |
Bristol Myers Squibb Co |
Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
AU2017308590A1
(en)
|
2016-08-12 |
2019-02-14 |
Janssen Biotech, Inc. |
Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
|
US11246905B2
(en)
|
2016-08-15 |
2022-02-15 |
President And Fellows Of Harvard College |
Treating infections using IdsD from Proteus mirabilis
|
US10751415B2
(en)
|
2016-08-17 |
2020-08-25 |
Compugen Ltd. |
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
|
CN106244611B
(zh)
*
|
2016-08-23 |
2019-05-17 |
浙江普康生物技术股份有限公司 |
一种细胞免疫佐剂tsa-41的制备方法及应用
|
JP2019528300A
(ja)
|
2016-08-26 |
2019-10-10 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法
|
CA3038020A1
(en)
|
2016-09-23 |
2018-03-29 |
Merus N.V. |
Bispecific binding molecules that bind cd137
|
JP2019530704A
(ja)
|
2016-10-06 |
2019-10-24 |
ファイザー・インコーポレイテッド |
がんの処置のためのアベルマブの投与レジメン
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
JP7274417B2
(ja)
*
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1bb結合タンパク質及びその使用
|
US11512134B2
(en)
|
2017-08-01 |
2022-11-29 |
Eli Lilly And Company |
Anti-CD137 antibodies
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
MX2019004692A
(es)
*
|
2017-01-06 |
2019-11-08 |
Eutilex Co Ltd |
Anticuerpos 4-1bb anti-humano y usos de los mismos.
|
MA47236A
(fr)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des agonistes de la superfamille des récepteurs du facteur de nécrose tumorale (tnfrsf) et des combinaisons thérapeutiques de til et d'agonistes de tnfrsf
|
WO2018186924A1
(en)
|
2017-01-17 |
2018-10-11 |
The University Of Chicago |
Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment
|
KR20190107097A
(ko)
|
2017-01-20 |
2019-09-18 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd137+ 세포의 고갈을 위한 조성물 및 방법
|
AU2018210272B2
(en)
|
2017-01-20 |
2022-02-24 |
Arcus Biosciences, Inc. |
Azolopyrimidine for the treatment of cancer-related disorders
|
AU2018218345A1
(en)
|
2017-02-10 |
2019-08-29 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
WO2018156740A1
(en)
|
2017-02-24 |
2018-08-30 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
WO2018183608A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
MX2019012223A
(es)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anticuerpos anti-cd137 y metodos de uso de los mismos.
|
AU2018256459B2
(en)
|
2017-04-21 |
2023-12-07 |
Ikena Oncology, Inc. |
Indole AHR inhibitors and uses thereof
|
WO2018201014A1
(en)
|
2017-04-28 |
2018-11-01 |
Five Prime Therapeutics, Inc. |
Methods of treatment with cd80 extracellular domain polypeptides
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP7189155B2
(ja)
|
2017-05-17 |
2022-12-13 |
アーカス バイオサイエンシズ インコーポレイティド |
癌関連障害の治療のためのキナゾリン-ピラゾール誘導体
|
SG10202111336RA
(en)
|
2017-06-01 |
2021-11-29 |
Compugen Ltd |
Triple combination antibody therapies
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
WO2018226336A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
|
CA3067909A1
(en)
|
2017-06-19 |
2018-12-27 |
Medicenna Therapeutics Inc. |
Uses and methods for il-2 superagonists, agonists, and fusions thereof
|
WO2019005638A2
(en)
*
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
ANTI-4-1BB ANTIBODIES AND METHODS OF PREPARATION AND USE
|
US11236049B2
(en)
|
2017-06-30 |
2022-02-01 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of IDO inhibitors
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
EP3655439A1
(en)
|
2017-07-20 |
2020-05-27 |
Aptevo Research and Development LLC |
Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
|
ES2932354T3
(es)
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
SG11202000747VA
(en)
*
|
2017-08-01 |
2020-02-27 |
Lilly Co Eli |
Anti-cd137 antibodies
|
CN111163766A
(zh)
|
2017-08-17 |
2020-05-15 |
医肯纳肿瘤学公司 |
Ahr抑制剂和其用途
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
KR102651946B1
(ko)
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
US10953032B2
(en)
|
2017-08-31 |
2021-03-23 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019046496A1
(en)
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
IL273432B
(en)
|
2017-09-22 |
2022-09-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
EP3470428A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Antibodies targeting cd137 and methods of use thereof
|
JP7212683B2
(ja)
|
2017-10-10 |
2023-01-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
JP7438939B2
(ja)
*
|
2017-10-10 |
2024-02-27 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
Cd137を標的とする抗体とその利用方法
|
BR112020006999A2
(pt)
|
2017-10-10 |
2020-10-06 |
Numab Therapeutics AG |
anticorpo multiespecífico, composição farmacêutica e método de produção
|
CN109651507B
(zh)
*
|
2017-10-12 |
2021-11-26 |
瑞阳(苏州)生物科技有限公司 |
一种激动型4-1bb单克隆抗体
|
JP7254821B2
(ja)
|
2017-10-16 |
2023-04-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
WO2019089753A2
(en)
*
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
JP2021501801A
(ja)
|
2017-11-01 |
2021-01-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の処置に用いるための免疫刺激アゴニスト抗体
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
JP7404252B2
(ja)
|
2017-11-08 |
2023-12-25 |
ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド |
生体分子のコンジュゲートおよびその使用
|
TWI701259B
(zh)
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
4﹘1bb抗體及其製備方法和應用
|
EP3710576A1
(en)
|
2017-11-17 |
2020-09-23 |
Iovance Biotherapeutics, Inc. |
Til expansion from fine needle aspirates and small biopsies
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019109238A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Lyvgen Biopharma Co., Ltd. |
Anti-cd137 antibodies and uses thereof
|
AU2018396142A1
(en)
|
2017-12-26 |
2020-07-16 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN110003332B
(zh)
*
|
2018-01-05 |
2021-05-11 |
上海原能细胞医学技术有限公司 |
Cd137抗体及其应用
|
CN117866899A
(zh)
|
2018-01-08 |
2024-04-12 |
艾欧凡斯生物治疗公司 |
产生富含肿瘤抗原特异性t细胞的til产品的方法
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
AU2019206724A1
(en)
*
|
2018-01-15 |
2020-07-16 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist
|
US20210363266A1
(en)
|
2018-01-22 |
2021-11-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Gcn2阻害剤およびその使用
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
JP2021512962A
(ja)
|
2018-02-13 |
2021-05-20 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
CA3093387A1
(en)
|
2018-03-08 |
2019-09-12 |
Rubius Therapeutics, Inc. |
Therapeutic cell systems and methods for treating cancer and infectious diseases
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
KR20200135421A
(ko)
|
2018-03-21 |
2020-12-02 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
KR20240017090A
(ko)
|
2018-03-23 |
2024-02-06 |
일라이 릴리 앤드 캄파니 |
항-pd-1 항체와의 조합을 위한 항-cd137 항체
|
KR102432046B1
(ko)
*
|
2018-03-23 |
2022-08-12 |
일라이 릴리 앤드 캄파니 |
항-pd-l1 항체와의 조합을 위한 항-cd137 항체
|
SG11202009170UA
(en)
|
2018-03-29 |
2020-10-29 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US20210230287A1
(en)
*
|
2018-04-10 |
2021-07-29 |
Wuxi Biologics (Shanghai) Co., Ltd. |
A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
EP3781162A1
(en)
|
2018-04-16 |
2021-02-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
CA3098303A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US20230339891A1
(en)
|
2018-05-03 |
2023-10-26 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
AU2019287765A1
(en)
|
2018-06-15 |
2021-01-07 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
CN112585139B
(zh)
|
2018-06-27 |
2023-12-01 |
百时美施贵宝公司 |
用作t细胞激活剂的萘啶酮化合物
|
CA3104654A1
(en)
|
2018-06-27 |
2020-01-02 |
Bristol-Myers Squibb Company |
Substituted naphthyridinone compounds useful as t cell activators
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
WO2020014132A2
(en)
|
2018-07-09 |
2020-01-16 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
EP3820902A2
(en)
|
2018-07-11 |
2021-05-19 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
CN112424229A
(zh)
|
2018-07-12 |
2021-02-26 |
F星贝塔有限公司 |
结合cd137和ox40的抗体分子
|
JP7360440B2
(ja)
|
2018-07-12 |
2023-10-12 |
エフ-スター セラピューティクス リミテッド |
Pd-l1及びcd137に結合する抗体分子
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
CN112334488B
(zh)
|
2018-07-19 |
2023-12-08 |
伊莱利利公司 |
靶向免疫检查点的双特异性抗体
|
US20210299126A1
(en)
|
2018-07-23 |
2021-09-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN112996509A
(zh)
|
2018-07-27 |
2021-06-18 |
艾库斯生物科学有限公司 |
吡啶酮a2r拮抗剂
|
PE20210343A1
(es)
|
2018-08-10 |
2021-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
CN113164419A
(zh)
|
2018-09-07 |
2021-07-23 |
皮克医疗公司 |
Eif4e抑制剂和其用途
|
KR20210064269A
(ko)
|
2018-09-20 |
2021-06-02 |
이오반스 바이오테라퓨틱스, 인크. |
동결보존된 종양 샘플로부터의 til의 확장
|
EP3863717A1
(en)
|
2018-10-09 |
2021-08-18 |
Numab Therapeutics AG |
Antibodies targeting cd137 and methods of use thereof
|
EP3636320A1
(en)
|
2018-10-09 |
2020-04-15 |
Numab Therapeutics AG |
Antibodies targeting cd137 and methods of use thereof
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
CA3115285A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
CN113272420A
(zh)
|
2018-11-05 |
2021-08-17 |
艾欧凡斯生物治疗公司 |
经改进的肿瘤反应性t细胞的选择
|
JOP20210094A1
(ar)
|
2018-11-05 |
2023-01-30 |
Iovance Biotherapeutics Inc |
عمليات لإنتاج الخلايا الليمفاوية للورم الارتشاحي واستخداماتها في العلاج المناعي
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
PE20211778A1
(es)
*
|
2018-11-30 |
2021-09-08 |
Abl Bio Inc |
Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos
|
JP2022516401A
(ja)
|
2018-11-30 |
2022-02-28 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
JP7476219B2
(ja)
|
2019-02-26 |
2024-04-30 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Cd137およびgpc3に特異的な新規融合タンパク質
|
KR20220012839A
(ko)
|
2019-03-19 |
2022-02-04 |
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 |
Omomyc와 pd-1 또는 ctla-4에 결합하는 항체를 이용한 암 치료용 조합 요법
|
MX2021011608A
(es)
|
2019-03-29 |
2021-12-10 |
Myst Therapeutics Llc |
Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
|
WO2020201753A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
TW202106676A
(zh)
|
2019-04-05 |
2021-02-16 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
JP2022530026A
(ja)
|
2019-04-24 |
2022-06-27 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アマトキシン抗体薬物複合体及びその使用
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
WO2020231809A1
(en)
|
2019-05-10 |
2020-11-19 |
Lyvgen Biopharma Co., Ltd. |
Humanized anti-cd137 antibodies and uses thereof
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
US20230242478A1
(en)
|
2019-05-13 |
2023-08-03 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
AU2020281535A1
(en)
|
2019-05-24 |
2022-01-27 |
Merck Patent Gmbh |
Combination therapies using CDK inhibitors
|
CA3141452A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
CN114206943A
(zh)
|
2019-06-04 |
2022-03-18 |
分子伴侣公司 |
多特异性蛋白质
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
WO2021050964A1
(en)
|
2019-09-13 |
2021-03-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
KR20220070254A
(ko)
|
2019-09-25 |
2022-05-30 |
화이자 인코포레이티드 |
Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
AU2020381735A1
(en)
|
2019-11-13 |
2022-05-26 |
Hefei Hankemab Biotechnology Co., Ltd |
Molecule capable of binding to human 4-1BB, and application of molecule
|
CN112898426A
(zh)
*
|
2019-11-19 |
2021-06-04 |
非同(成都)生物科技有限公司 |
人源化4-1bb单克隆抗体及其药物组合物
|
IL293027A
(en)
|
2019-11-19 |
2022-07-01 |
Bristol Myers Squibb Co |
Compounds useful as inhibitors of Helios protein
|
AU2020393854A1
(en)
|
2019-11-26 |
2022-06-09 |
Bristol-Myers Squibb Company |
Salts/cocrystals of (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
EP4065582A1
(en)
|
2019-11-26 |
2022-10-05 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
JP2023504042A
(ja)
|
2019-11-27 |
2023-02-01 |
ミスト セラピューティクス リミテッド ライアビリティ カンパニー |
調節物質を使用した腫瘍反応性t細胞組成物の生成方法
|
WO2021118990A1
(en)
|
2019-12-11 |
2021-06-17 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
CA3164804A1
(en)
|
2019-12-18 |
2021-06-24 |
Pfizer Inc. |
Once daily cancer treatment regimen with a prmt5 inhibitor
|
JP2023508375A
(ja)
|
2019-12-23 |
2023-03-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換ピペラジン誘導体
|
BR112022012179A2
(pt)
|
2019-12-23 |
2022-09-06 |
Bristol Myers Squibb Co |
Compostos de quinazolina substituída úteis como ativadores de célula t
|
JP2023508055A
(ja)
|
2019-12-23 |
2023-02-28 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
BR112022012204A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Compostos de heteroarila substituída úteis como ativadores de célula t
|
MX2022007841A
(es)
|
2019-12-23 |
2022-07-19 |
Kymera Therapeutics Inc |
Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
|
WO2021141907A1
(en)
|
2020-01-06 |
2021-07-15 |
Hifibio (Hong Kong) Limited |
Anti-tnfr2 antibody and uses thereof
|
WO2021139682A1
(en)
|
2020-01-07 |
2021-07-15 |
Hifibio (Hk) Limited |
Anti-galectin-9 antibody and uses thereof
|
KR20220124718A
(ko)
|
2020-01-07 |
2022-09-14 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체
|
CN115279771A
(zh)
|
2020-01-15 |
2022-11-01 |
缆图药品公司 |
Map4k1抑制剂
|
TW202144395A
(zh)
*
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
BR112022016490A2
(pt)
|
2020-02-27 |
2022-10-11 |
Myst Therapeutics Llc |
Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas
|
CN115066440A
(zh)
|
2020-02-28 |
2022-09-16 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体及其用途
|
WO2021170071A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
CN115298165A
(zh)
|
2020-03-19 |
2022-11-04 |
艾库斯生物科学有限公司 |
作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
|
CA3171258A1
(en)
|
2020-03-19 |
2021-09-23 |
Nan JI |
Mdm2 degraders and uses thereof
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
JP2023523855A
(ja)
|
2020-05-04 |
2023-06-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
|
JP2023524108A
(ja)
|
2020-05-04 |
2023-06-08 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
改良された腫瘍反応性t細胞の選択
|
CA3182887A1
(en)
|
2020-05-13 |
2021-11-18 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
PE20231078A1
(es)
|
2020-06-02 |
2023-07-17 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
CA3184366A1
(en)
|
2020-06-29 |
2022-01-06 |
Darby Rye Schmidt |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
BR112023001638A2
(pt)
|
2020-07-30 |
2023-02-23 |
Kymera Therapeutics Inc |
Métodos de tratamento de linfomas mutantes
|
WO2022033419A2
(en)
|
2020-08-10 |
2022-02-17 |
Shanghai Xbh Biotechnology Co., Ltd. |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
IL300884A
(en)
|
2020-09-14 |
2023-04-01 |
Pfizer |
Treatment methods and uses for cancer treatment
|
CN114195894A
(zh)
*
|
2020-09-17 |
2022-03-18 |
普米斯生物技术(珠海)有限公司 |
一种靶向4-1bb的抗体及其应用
|
CN114195900B
(zh)
|
2020-09-17 |
2024-02-23 |
普米斯生物技术(珠海)有限公司 |
一种抗4-1bb/pd-l1双特异性抗体及其用途
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
EP3988568A1
(en)
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
CN117015531A
(zh)
|
2020-12-02 |
2023-11-07 |
医肯纳肿瘤学公司 |
Tead抑制剂及其用途
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
EP4262986A1
(en)
|
2020-12-16 |
2023-10-25 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
EP4262827A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
TW202241488A
(zh)
|
2021-01-11 |
2022-11-01 |
英商拜斯科技技術開發有限公司 |
治療癌症之方法
|
WO2022153161A1
(en)
|
2021-01-14 |
2022-07-21 |
Pfizer Inc. |
Treatment of cancer using a prmt5 inhibitor
|
WO2022167445A1
(en)
|
2021-02-02 |
2022-08-11 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
WO2022167457A1
(en)
|
2021-02-02 |
2022-08-11 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
EP4288140A1
(en)
|
2021-02-05 |
2023-12-13 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
PE20231505A1
(es)
|
2021-02-12 |
2023-09-26 |
Hoffmann La Roche |
Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer
|
US11773103B2
(en)
|
2021-02-15 |
2023-10-03 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
TW202300014A
(zh)
|
2021-03-05 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
腫瘤儲存及細胞培養組成物
|
EP4301756A1
(en)
|
2021-03-05 |
2024-01-10 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
AU2022246895A1
(en)
|
2021-03-31 |
2023-10-19 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
IL307338A
(en)
|
2021-04-05 |
2023-11-01 |
Bristol Myers Squibb Co |
Pyridinyl substituted oxisoisoindoline compounds for cancer therapy
|
WO2022216644A1
(en)
|
2021-04-06 |
2022-10-13 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
KR20240037185A
(ko)
|
2021-04-19 |
2024-03-21 |
이오반스 바이오테라퓨틱스, 인크. |
키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
EP4341262A1
(en)
|
2021-05-21 |
2024-03-27 |
Arcus Biosciences, Inc. |
Axl inhibitor compounds
|
EP4341261A1
(en)
|
2021-05-21 |
2024-03-27 |
Arcus Biosciences, Inc. |
Axl compounds
|
WO2022261018A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
AU2022312496A1
(en)
|
2021-07-14 |
2024-02-22 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
WO2023288264A1
(en)
|
2021-07-15 |
2023-01-19 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
WO2023061421A1
(en)
*
|
2021-10-12 |
2023-04-20 |
Concept To Medicine Biotech Co., Ltd. |
Single-domain 4-1bb antibodies
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
WO2023077046A1
(en)
|
2021-10-29 |
2023-05-04 |
Arcus Biosciences, Inc. |
Inhibitors of hif-2alpha and methods of use thereof
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
US20240124490A1
(en)
|
2022-07-15 |
2024-04-18 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024081385A1
(en)
|
2022-10-14 |
2024-04-18 |
Arcus Biosciences, Inc. |
Hpk1 inhibitors and methods of use thereof
|